Differential expression of microRNA501-5p affects the aggressiveness of clear cell renal carcinoma

FEBS Open Bio

Volumn 4, Issue , 2014, Pages 952-965

  Mangolini, Alessandra ^a   Bonon, Anna ^a   Volinia, Stefano ^a   Lanza, Giovanni ^b   Gambari, Roberto ^a   Pinton, Paolo ^a   Russo, Gian Rosario ^c   del Senno, Laura ^a   Dell'Atti, Lucio ^c   Aguiari, Gianluca ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^c S ANNA HOSPITAL   (Italy)

Author keywords

Apoptosis; Cell survival; MicroRNA501 5p; MTOR signaling; P53

Indexed keywords

CASPASE 3; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MICRORNA 501 5P; PROTEIN MDM2; PROTEIN P53; SMALL UNTRANSLATED RNA; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY CELL; KIDNEY PARENCHYMA; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA DEGRADATION; UBIQUITINATION; WESTERN BLOTTING;

EID: 84910593589     PISSN: 22115463     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fob.2014.10.016     Document Type: Article

References (40)

1. Aguiari G., Piva R., Manzati E., Mazzoni E., Augello G., Chiari E., Moretti S., Neri L.M., del Senno L. K562 erythroid and HL60 macrophage differentiation downregulates polycystin, a large membrane-associated protein. Exp. Cell Res. 1998, 244:259-267.
2. Aguiari G., Campanella M., Manzati E., Pinton P., Banzi M., Moretti S., Piva R., Rizzuto R., del Senno L. Expression of polycystin 1 C-terminal fragment enhances the ATP-induced Ca2+ release in human kidney cells. Biochem. Biophys. Res. Commun. 2003, 301:657-664.
3. Aguiari G., Varani K., Bogo M., Mangolini A., Vincenzi F., Durante C., Gessi S., Sacchetto V., Catizone L., Harris P., Rizzuto R., Borea P.A., Del Senno L. Deficiency of polycystic kidney disease-1 gene (PKD1) expression increases A(3) adenosine receptors in human renal cells: implications for cAMP-dependent signalling and proliferation of PKD1-mutated cystic cells. Biochim. Biophys. Acta 2009, 1792:531-540.
4. Aguiari G., Bizzarri F., Bonon A., Mangolini A., Magri E., Pedriali M., Querzoli P., Somlo S., Harris P.C., Catizone L., Del Senno L. Polycystin-1 regulates amphiregulin expression through CREB and AP1 signalling: implications in ADPKD cell proliferation. J. Mol. Med. (Berl.) 2012, 90:1267-1282.
5. Barletta C., Bartolazzi A., Cimino Reale G., Gambari R., Nastruzzi C., Barbieri R., Del Senno L., Castagnoli A., Natali P.G. Cytogenetic, molecular and phenotypic characterization of the newly established renal carcinoma cell line KJ29. Evidence of translocations for chromosomes 1 and 3. Anticancer Res. 1995, 15:2129-2136.
6. Belibi F.A., Edelstein C.L. Metastatic renal cancer: what role for everolimus?. Clin. Med. Rev. Oncol. 2010, 2:4.
7. Berg W.J., Divgi C.R., Nanus D.M., Motzer R.J. Novel investigative approaches for advanced renal cell carcinoma. Semin. Oncol. 2000, 27:234-239.
8. Bonon A., Mangolini A., Pinton P., Del Senno L., Aguiari G. Berberine slows cell growth in autosomal dominant polycystic kidney disease cells. Biochem. Biophys. Res. Commun. 2013, 441:668-674.
9. Cairns P. Renal cell carcinoma. Cancer Biomark. 2010, 9:461-473.
10. Dey N., Das F., Ghosh-Choudhury N., Mandal C.C., Parekh D.J., Block K., Kasinath B.S., Abboud H.E., Choudhury G.G. MicroRNA-21 governs TORC1 activation in renal cancer cell proliferation and invasion. PLoS One 2012, 7:e37366.
11. Di Leva G., Croce C.M. Roles of small RNAs in tumor formation. Trends Mol. Med. 2010, 16:257-267.
12. Di Leva G., Croce C.M. miRNA profiling of cancer. Curr. Opin. Genet. Dev. 2013, 23:3-11.
13. Du W., Yi Y., Zhang H., Bergholz J., Wu J., Ying H., Zhang Y., Xiao Z.X. Rapamycin inhibits IGF-1-mediated up-regulation of MDM2 and sensitizes cancer cells to chemotherapy. PLoS One 2013, 8:e63179.
14. Elorza A., Soro-Arnáiz I., Meléndez-Rodríguez F., Rodríguez-Vaello V., Marsboom G., de Cárcer G., Acosta-Iborra B., Albacete-Albacete L., Ordóñez A., Serrano-Oviedo L., Giménez-Bachs J.M., Vara-Vega A., Salinas A., Sánchez-Prieto R., Martín del Río R., Sánchez-Madrid F., Malumbres M., Landázuri M.O., Aragonés J. HIF2α acts as an mTORC1 activator through the amino acid carrier SLC7A5. Mol. Cell 2012, 48:681-691.
15. Haddad H., Rini B.I. Current treatment considerations in metastatic renal cell carcinoma. Curr. Treat. Options Oncol. 2012, 13:212-229.
16. *, miR-191, miR-337-3p and miR-378) as potential biomarkers in renal cell carcinoma. Cancer Epidemiol. 2012, 36:391-394.
17. Henrique R., Luís A.S., Jerónimo C. The epigenetics of renal cell tumors: from biology to biomarkers. Front. Genet. 2012, 30(3):94.
18. Janssen E.A., Slewa A., Gudlaugsson E., Jonsdottir K., Skaland I., Søiland H., Baak J.P. Biologic profiling of lymph node negative breast cancers by means of microRNA expression. Mod. Pathol. 2010, 23:1567-1576.
19. Lieberthal W., Levine J.S. The role of the mammalian target of rapamycin (mTOR) in renal disease. J. Am. Soc. Nephrol. 2009, 20:2493-2502.
20. Loghman-Adham M., Nauli S.M., Soto C.E., Kariuki B., Zhou J. Immortalized epithelial cells from human autosomal polycystic kidney cysts. Am. J. Physiol. Renal Physiol. 2003, 285:F397-F412.
21. Mangolini A., Bogo M., Durante C., Borgatti M., Gambari R., Harris P.C., Rizzuto R., Pinton P., Aguiari G., del Senno L. NF-kappaB activation is required for apoptosis in fibrocystin/polyductin-depleted kidney epithelial cells. Apoptosis 2010, 15:94-104.
22. Moch H., Srigley J., Delahunt B., Montironi R., Egevad L., Tan P.H. Biomarkers in renal cancer. Virchows Arch. 2014, 464:359-365.
23. Moumen A., Patané S., Porras A., Dono R., Maina F. Met acts on Mdm2 via mTOR to signal cell survival during development. Development 2007, 134:1443-1451.
24. Negrini M., Cutrona G., Bassi C., Fabris S., Zagatti B., Colombo M., Ferracin M., D'Abundo L., Saccenti E., Matis S., Lionetti M., Agnelli L., Gentile M., Recchia A.G., Bossio S., Reverberi D., Rigolin G., Calin G.A., Sabbioni S., Russo G., Tassone P., Morabito F., Ferrarini M., Neri A. microRNAome expression in chronic lymphocytic leukemia: comparison with normal B-cell subsets and correlations with prognostic and clinical parameters. Clin. Cancer Res. 2014, 20:4141-4153.
25. Noon A.P., Polański R., El-Fert A.Y., Kalirai H., Shawki H., Campbell F., Dodson A., Eccles R.M., Lloyd B.H., Sibson D.R., Coupland S.E., Lake S.L., Parsons K., Vlatković N., Boyd M.T. Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy. BJU Int. 2012, 109:1250-1257.
26. Okamoto K., Taya Y., Nakagama H. Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase. FEBS Lett. 2009, 583:2710-2714.
27. Oliver T.G., Meylan E., Chang G.P., Xue W., Burke J.R., Humpton T.J., Hubbard D., Bhutkar A., Jacks T. Caspase-2-mediated cleavage of Mdm2 creates a p53-induced positive feedback loop. Mol. Cell 2011, 43:57-71.
28. Pantuck A.J., Seligson D.B., Klatte T., Yu H., Leppert J.T., Moore L., O'Toole T., Gibbons J., Belldegrun A.S., Figlin R.A. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 2007, 109:2257-2267.
29. Petillo D., Kort E.J., Anema J., Furge K.A., Yang X.J., Teh B.T. MicroRNA profiling of human kidney cancer subtypes. Int. J. Oncol. 2009, 35:109-114.
30. Ranaweera R.S., Yang X. Auto-ubiquitination of Mdm2 enhances its substrate ubiquitin ligase activity. J. Biol. Chem. 2013, 288:18939-18946.
31. Redova M., Svoboda M., Slaby O. MicroRNAs and their target gene networks in renal cell carcinoma. Biochem. Biophys. Res. Commun. 2011, 405:153-156.
32. Robb V.A., Karbowniczek M., Klein-Szanto A.J., Henske E.P. Activation of the mTOR signaling pathway in renal clear cell carcinoma. J. Urol. 2007, 177:346-352.
33. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J. Clin. 2014, 64:9-29.
34. Sun S.Y. mTOR kinase inhibitors as potential cancer therapeutic drugs. Cancer Lett. 2013, 340:1-8.
35. Vasudev N.S., Selby P.J., Banks R.E. Renal cancer biomarkers: the promise of personalized care. BMC Med. 2012, 10:112.
36. Warburton H.E., Brady M., Vlatković N., Linehan W.M., Parsons K., Boyd M.T. p53 regulation and function in renal cell carcinoma. Cancer Res. 2005, 65:6498-6503.
37. Weston M.C., Chen H., Swann J.W. Loss of mTOR repressors Tsc1 or Pten has divergent effects on excitatory and inhibitory synaptic transmission in single hippocampal neuron cultures. Front. Mol. Neurosci. 2014, 7:1.
38. Xia J.T., Chen L.Z., Jian W.H., Wang K.B., Yang Y.Z., He W.L., He Y.L., Chen D., Li W. MicroRNA-362 induces cell proliferation and apoptosis resistance in gastric cancer by activation of NF-κB signaling. J. Transl. Med. 2014, 12:33.
39. Yamamoto Y., Kosaka N., Tanaka M., Koizumi F., Kanai Y., Mizutani T., Murakami Y., Kuroda M., Miyajima A., Kato T., Ochiya T. MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma. Biomarkers 2009, 14:529-538.
40. Zigeuner R., Ratschek M., Rehak P., Schips L., Langner C. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue. Urology 2004, 63:651-655.